EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL

Sanjay Sethi iD, Brendan Clark iD, Erin K Buysman iD, Andrew Sargent iD, Lindsay G S Bengtson iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s534974 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Sanjay Sethi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Quinuclidines, Tiotropium Bromide. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsQuinuclidinesTiotropium BromideBenzyl AlcoholsEosinophilsChlorobenzenesAdrenergic beta-2 Receptor AgonistsLungHumansMaleFemaleRetrospective StudiesAgedDrug CombinationsTreatment OutcomeMiddle AgedAdministration, InhalationLeukocyte CountDatabases, FactualTime FactorsDisease ProgressionAndrostadienesBenzoxazines

Stichwörter der Autor:innen

claimscostsdual bronchodilatoreosinophilexacerbationstriple therapy

Substanzen

vilanterolBronchodilator AgentsDrug CombinationsGSK573719QuinuclidinesTiotropium BromideBenzyl Alcoholsfluticasone furoateChlorobenzenesAdrenergic beta-2 Receptor Agonists

Autor:innen und Institutionen

  • Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
  • HEOR Value Demonstration, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Health Economics and Outcomes Research, Optum Life Sciences, Eden Prairie, MN, USA.

ORCID-Profile: Sanjay Sethi, Brendan Clark, Erin K Buysman, Andrew Sargent, Lindsay G S Bengtson

Zitieren

APA

Sethi, S., Clark, B., Buysman, E. K., Sargent, A., & Bengtson, L. G. S. (2025). Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s534974

Vancouver

Sethi S, Clark B, Buysman EK, Sargent A, Bengtson LGS. Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s534974

BibTeX
@article{Sethi2025,
  author = {Sethi, Sanjay and Clark, Brendan and Buysman, Erin K and Sargent, Andrew and Bengtson, Lindsay G S},
  title = {Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s534974}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche